STOCK TITAN

Vericel - VCEL STOCK NEWS

Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.

Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.

Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:

- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms

Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.

Rhea-AI Summary
Vericel Corporation's CEO to participate in fireside chat at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reported a record second quarter total revenue of $45.9 million, with 24% growth versus the prior year. MACI revenue grew by 27% to $36.3 million, and Epicel revenue grew by 17% to $9.6 million. The full-year 2023 revenue guidance has been raised to $190-197 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
conferences earnings
Rhea-AI Summary
Vericel Corporation reported record first-quarter total revenue of $41 million, with MACI revenue increasing by 32% to $34.2 million. Full-year 2023 revenue guidance has been raised to $184-$192 million. The company also highlighted positive business highlights, including the highest number of surgeons using MACI biopsies and progress on the NexoBrid program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
-
Rhea-AI Summary
Dimension Inx announces the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton brings expertise in platform growth opportunities and has experience leading biotechnology and pharmaceutical companies. Mr. Ehrlich will focus on corporate development and financial strategy. Dimension Inx is a biomaterials platform company developing therapeutics for tissue and organ restoration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
-
Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) is scheduled to report its first-quarter 2023 financial results on May 10, 2023. The company specializes in advanced therapies for sports medicine and serious burn care, offering products such as MACI® and Epicel®. A conference call will take place at 8:30 a.m. (ET) to discuss the results and key business highlights, accessible through the Investor Relations section of its website. Interested participants should register in advance to obtain dial-in details. A replay will be available until May 10, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences earnings
Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Musculoskeletal Conference on March 7, 2023, at 12:30 p.m. ET. A webcast of this presentation can be accessed through Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI®, an autologous scaffold for knee cartilage defects, and Epicel®, a permanent skin replacement for severe burns. Vericel also holds exclusive rights to NexoBrid® for burn treatment. For further details, visit the company's official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences
-
Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) reported robust financial results for Q4 and full-year 2022, with total revenue reaching $52.7 million in Q4, a 31% increase in net income, and total annual revenue of $164.4 million. MACI revenue contributed $132 million for 2022, showing a 24% year-over-year growth in Q4. The company anticipates 2023 total revenue between $180 million and $188 million with MACI revenue estimated at $152 million to $156 million. Notably, Vericel achieved FDA approval for NexoBrid, paving the way for further growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.29%
Tags
-
Rhea-AI Summary

Vericel Corporation (NASDAQ: VCEL) is set to report its fourth-quarter 2022 financial results on February 23, 2023. Management will host a conference call and webcast at 8:30 a.m. (ET) to discuss these results along with important business highlights. Interested participants can access the live webcast on Vericel's Investor Relations page and register for the call via the provided link to receive dial-in details. A replay will be available on their website until February 23, 2024. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing notable products like MACI® and Epicel®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
conferences earnings
Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) reported preliminary financial results for 2022, with total revenue expected between $164 to $165 million. MACI revenue is expected at around $132 million, while Burn Care revenue approximates $32.5 million. Notably, MACI revenue is anticipated to grow by 24% in Q4 compared to the previous year. The company plans to accelerate the launch of MACI’s arthroscopic delivery to 2024 and expects positive adjusted EBITDA for the tenth consecutive quarter. As of year-end 2022, Vericel had around $140 million in cash, with no debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.27%
Tags
Vericel

Nasdaq:VCEL

VCEL Rankings

VCEL Stock Data

2.07B
49.62M
1.03%
106.6%
7.79%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE